Skip to main content

Table 2 Allelic frequencies and case-control association analysis with ASDs in the primary and sex-specific analyses within the NLGN3 and NLGN4X genes

From: A sex-specific association of common variants of neuroligin genes (NLGN3 and NLGN4X) with autism spectrum disorders in a Chinese Han cohort

    

Total samples (N = 420)

Male samples (N = 333)

Female samples (N = 87)

Genes

SNP

Position in gene

Assoc Allele

Allele counts in controls(%)

Allele counts in cases(%)

P value

P corr value

OR (95%CI)

Allele counts in controls(%)

Allele counts in cases(%)

P value

P corr value

OR (95%CI)

Allele counts in controls(%)

Allele counts in cases(%)

P value

P corr value

OR (95%CI)

NLGN3

rs11795613 (G/A)

Intron1

XA

150(62.5%)

199(74.5%)

0.0035

0.021

1.756 (1.201-2.567)

84 (59.2%)

137(71.7%)

0.0163

ns

1.752

(1.106-2.774)

66 (67.3%)

62(81.6%)

0.035

ns

2.147

(1.048-4.4)

 

rs4844285 (A/G)

Intron2

XG

149(62.6%)

201(75.6%)

0.0016

0.0097

1.847 (1.259-2.711)

83 (59.3%)

139(73.2%)

0.0079

0.048

1.872

(1.175-2.981)

66 (67.3%)

62(81.6%)

0.035

ns

2.147

(1.048-4.4)

 

rs4844286 (G/T)

Intron2

XT

163(67.9%)

206(77.2%)

0.0196

ns

1.595 (1.076-2.365)

95 (66.9%)

145(75.9%)

0.07

ns

1.559

(0.963-2.525)

68 (69.4%)

61(80.3%)

0.104

ns

1.794

(0.882-3.648)

 

rs5981079 (C/T)

Intron2

XT

132(55.5%)

175(67.0%)

0.0079

0.047

1.634 (1.136-2.35)

79 (55.6%)

126(66.7%)

0.041

ns

1.595

(1.019-2.497)

53 (55.2%)

49(68.1%)

0.092

ns

1.728

(0.913-3.272)

 

rs7051529 (G/A)

Intron4

XA

132(58.9%)

182(68.7%)

0.025

ns

1.528 (1.054-2.217)

73 (56.2%)

125(65.4%)

0.093

ns

1.479

(0.936-2.336)

59 (62.8%)

57(77.0%)

0.047

ns

1.989

(1.003-3.943)

 

rs10127395 (G/T)

Intron5

XT

196(81.7%)

221(83.1%)

0.676

ns

1.102 (0.698-1.743)

117(82.4%)

158(83.2%)

0.855

ns

1.055

(0.594-1.875)

79 (80.6%)

63(82.9%)

0.700

ns

1.166

(0.535-2.541)

NLGN4X

rs6529901 (G/A)

Intron3

XA

129(55.8%)

150(56.8%)

0.827

ns

1.04 (0.729-1.485)

82 (58.2%)

104(54.7%)

0.535

ns

0.87

(0.56-1.351)

47 (52.2%)

46(62.2%)

0.201

ns

1.503

(0.804-2.812)

 

rs5961397 (G/A)

Intron3

XA

176(73.6%)

198(74.2%)

0.895

ns

1.027 (0.69-1.528)

106(75.2%)

134(70.2%)

0.312

ns

0.776

(0.475-1.27)

70 (71.4%)

64(84.2%)

0.047

ns

2.133

(1.001-4.545)

 

rs4370667 (C/T)

Intron2

XT

183(80.6%)

212(80.0%)

0.864

ns

0.962 (0.616-1.502)

112(81.8%)

150(79.4%)

0.592

ns

0.859

(0.491-1.501)

71 (78.9%)

62(81.6%)

0.665

ns

1.185

(0.549-2.559)

 

rs10522049 (G/A)

Intron2

XA

198(82.8%)

223(83.5%)

0.839

ns

1.049 (0.658-1.35)

114(80.9%)

157(82.2%)

0.754

ns

1.094

(0.625-1.914)

84 (85.7%)

66(86.8%)

0.831

ns

1.1

(0.46-2.634)

 

rs1882409 (A/G)

Intron1

XA

69(29.0%)

82(30.7%)

0.673

ns

1.086 (0.741-1.591)

42 (30.0%)

59(30.9%)

0.862

ns

1.043

(0.649-1.676)

27(27.6%)

23(30.3%)

0.695

ns

1.141

(0.590-2.208)

 

rs5916352 (G/C)

Intron1

XC

184(77.0%)

215(81.7%)

0.187

ns

1.339 (0.867-2.067)

34 (24.1%)

32(17.1%)

0.117

ns

0.65

(0.378-1.117)

21 (21.4%)

16(21.1%)

0.952

ns

1.023

(0.492-2.128)

  1. Assoc Allele, associated allele; OR, odds ratio; 95%CI, 95% confidence interval; Pcorr value, corrected by Bonferroni's approach for multiple testing, ns, not significant. Male samples (n = 333) include 191 cases and 142 controls, female samples (n = 87) include 38 cases and 49 controls. Significant P-values are indicated in bold.